Physician profile
Luis E Gaitan
NPI 1275605974
$2,202.46
in general payments reported to CMS, 2019-2025
30 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $350 · 2021: $110 · 2022: $267 · 2023: $176 · 2024: $154 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477 · Education: $66.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.80 |
| Education | $66.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $317.67 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $244.56 | 2019-2021 | |
| Ucb, INC. | $130.90 | 2019-2024 | Fintepla |
| Acadia Pharmaceuticals INC | $124.71 | 2019 | |
| Eisai INC. | $124.49 | 2024 | |
| Imperative Care, INC | $123.97 | 2022 | |
| Kyowa Kirin, INC. | $123.82 | 2020 | |
| Acorda Therapeutics, INC | $109.59 | 2020 | |
| Medtronic, INC. | $108.12 | 2022 | |
| Sunovion Pharmaceuticals INC. | $102.19 | 2019 | |
| Genzyme Corporation | $95.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.38 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $66.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $55.44 | 2020-2021 | |
| Otter Pharmaceuticals, LLC | $48.36 | 2025 | Sympazan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $47.70 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $36.00 | 2025 | |
| Neurocrine Biosciences, INC. | $34.94 | 2023 | Ongentys, Ingrezza |
| Sk Life Science, INC. | $27.66 | 2025 | |
| Lilly USA, LLC | $27.54 | 2019 | |
| Genentech USA, INC. | $19.78 | 2019 | |
| Amgen INC. | $19.30 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.98 | 2019 | |
| Corium, LLC | $18.87 | 2023 | Adlarity |
| Mdd US Operations, LLC | $17.88 | 2021 | |
| Strongbridge US INC. | $16.80 | 2020 | |
| Pfizer INC. | $16.74 | 2021 | |
| Lundbeck LLC | $15.89 | 2025 | Vyepti |
| Aucta Pharmaceuticals, INC. | $15.26 | 2024 | Motpoly Xr |
| Sumitomo Pharma America, INC. | $11.83 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gaitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.